We further show that obinutuzumab, a type 2 anti-CD20 antibody with similar affinity to CD20 but enhanced affinity to CD16 [25] is more potent in activating GPA NK cells than rituximab. The gene discussed is FCGR3A; the disease is granulomatosis with polyangiitis.